Nektar Therapeutics (NKTR) Convertible Debt (2010 - 2011)
Nektar Therapeutics' (NKTR) quarterly Convertible Debt came in at $215.0 million in Q4 2011, little changed year-on-year from $215.0 million in Q4 2010, and little changed quarter-over-quarter from $215.0 million in Q2 2011.
Nektar Therapeutics (NKTR) Convertible Debt (2010 - 2011) Analysis & Trends
Nektar Therapeutics' Convertible Debt history runs 2 years deep, the most recent figure standing at $215.0 million for Q4 2011.
- On a quarterly basis, Convertible Debt changed 0.0% year-over-year to $215.0 million in Q4 2011; TTM through Dec 2011 was $215.0 million, a 0.0% change from a year earlier, with the FY2011 full-year figure at $215.0 million, changed 0.0% from the prior year.
- Convertible Debt was little changed at $215.0 million in Q4 2011 per NKTR's latest filing, from $215.0 million in the prior quarter.
- Across five years, Convertible Debt topped out at $215.0 million in Q4 2010 and bottomed at $215.0 million in Q4 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Nektar Therapeutics | 2.04 Bn | 1.48 Bn | 3.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | 214.96 Mn |
| Jun 30, 2011 | 214.96 Mn |
| Mar 31, 2011 | 214.96 Mn |
| Dec 31, 2010 | 214.96 Mn |